AVRO - AVROBIOAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $15.68 | Open | $15.88 |
| Volume | 245.4K | Market Cap | 571.42M |
| Yield | Last Dividend |
| AVROBIO Receives Orphan Drug Designation... | 09/28/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at Three Upcoming Inv... | 09/03/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO : at the 2020 Wedbush PacGrow He... | 08/12/20 |
| Company Presentation Wedbush PacGrow Healthcare Virtual Conference August 2020 Disclaimer ??? | August 12, 2020 | |
| AVROBIO : Investor Presentation August 2... | 08/06/20 |
| Company Presentation August 2020 Disclaimer This??? | August 6, 2020 | |
| AVROBIO Reports Second Quarter 2020 Fina... | 08/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people ... | |
| AVROBIO Announces Inducement Grants Unde... | 07/08/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li... | |
| AVROBIO Announces New Patients Dosed in ... | 07/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces the Appointment of Kim... | 06/29/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Presents New Preclinical Data on... | 05/14/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Reports Updated Clinical Data fr... | 05/13/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| Why Earnings Season Could Be Great for A... | 05/08/20 |
| AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | |
| AVROBIO Reports 1Q 2020 Financial Result... | 05/07/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO and Magenta Therapeutics Announc... | 05/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clini... | |
| AVROBIO to Present New Clinical and Prec... | 05/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Collaborate with Saladax Biom... | 05/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| Is AVROBIO (AVRO) Stock a Solid Choice R... | 04/14/20 |
| AVROBIO (AVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| AVROBIO Outlines Response to COVID-19 an... | 03/30/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people ... | |
| AVROBIO to Participate in Upcoming April... | 03/26/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 03/17/20 |
| LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. | |
| AVROBIO Reports Fourth Quarter and Fisca... | 03/16/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Receives Orphan Drug Designation... | 03/09/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at the Cowen and Comp... | 02/24/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Closing of Underwritte... | 02/18/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing o... | |
| AVROBIO Announces Pricing of Underwritte... | 02/12/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing ... | |
| AVROBIO Presents Positive Initial Data f... | 02/10/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Clinical Data Presenta... | 02/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Clinical and Regulator... | 01/14/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO (NASDAQ: AVRO) (the ???Company???), a leading clinical-stage gene therapy company with a mission ... | |
| AVROBIO Announces First Patient Dosed Us... | 12/19/19 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO (NASDAQ: AVRO) (the ???Company???), a leading clinical-stage gene therapy company with a mission ... | |
| AVROBIO, Inc. Reports Third Quarter 2019... | 11/07/19 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO) (the ???Company???), a Phase 2 clinical-stage gene therapy company, today re... | |
| AVROBIO, Inc. (AVRO): Are Hedge Funds Ri... | 11/06/19 |
| A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors ... | |
| Strong Buy rating | 10/13/20 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $35.00 to $34.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
| Preticks | Hakan Moray | 0.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
